Literature DB >> 28757258

BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.

Elisabetta Tronci1, Francesco Napolitano2, Ana Muñoz3, Camino Fidalgo4, Francesca Rossi1, Anders Björklund5, Alessandro Usiello6, Manolo Carta7.   

Abstract

In addition to its role in neuronal survival, the brain neurotrophic factor (BDNF) has been shown to influence serotonin transmission and synaptic plasticity, events strongly implicated in the appearance of l-DOPA-induced dyskinesia (LID), a motor complication occurring in parkinsonian patients after long-term treatment with the dopamine precursor. In order to evaluate a possible influence of BDNF in the appearance of LID, 6-OHDA-lesioned rats received a striatal injection of different concentrations of an adeno-associated viral (AAV) vector over-expressing either BDNF or GFP, as control vector. Eight weeks later, animals started to receive a daily treatment with l-DOPA (4-6mg/kg plus benserazide 4-6mg/kg, s.c.) or saline, and dyskinesias, as well as l-DOPA-induced rotations, were evaluated at several time-points. Moreover, molecular changes in striatal D1 receptor-dependent cAMP/PKA and ERK/mTORC signaling pathways, as well as, sprouting of striatal serotonin axons, were measured. Results showed that the AAV-BDNF vector injection induced striatal over-expression of BDNF, as well as striatal and pallidal serotonin axon hyperinnervation. Moreover, rats that over-expressed BDNF were more prone to develop LID and l-DOPA-induced rotations, compared to the GFP-treated control group. Finally, rats that over-expressed BDNF showed increased levels of striatal D1R-dependent signaling phospho-proteins in response to l-DOPA administration. This study suggests that BDNF over-expression, by inducing changes in pre-synaptic serotonin axonal trophism, is able to exacerbate maladaptive responses to l-DOPA administration.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  6-OHDA; BDNF; Dyskinesia; LID; Parkinson's disease; SERT; Serotonin

Mesh:

Substances:

Year:  2017        PMID: 28757258     DOI: 10.1016/j.expneurol.2017.07.017

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  12 in total

Review 1.  The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective.

Authors:  Manolo Carta; Anders Björklund
Journal:  J Neural Transm (Vienna)       Date:  2018-02-26       Impact factor: 3.575

2.  Imaging SERT Availability in a Rat Model of L-DOPA-Induced Dyskinesia.

Authors:  Michael Walker; Laura Kuebler; Chris Marc Goehring; Bernd J Pichler; Kristina Herfert
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

3.  Levodopa-induced dyskinesia in Parkinson's disease: still no proof? A meta-analysis.

Authors:  Alexandros Giannakis; Maria Chondrogiorgi; Christos Tsironis; Athina Tatsioni; Spiridon Konitsiotis
Journal:  J Neural Transm (Vienna)       Date:  2018-01-19       Impact factor: 3.575

Review 4.  Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Authors:  Augusta Pisanu; Laura Boi; Giovanna Mulas; Saturnino Spiga; Sandro Fenu; Anna R Carta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-14       Impact factor: 3.575

5.  Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation.

Authors:  Sakari Leino; Samuel Kohtala; Tomi Rantamäki; Sini K Koski; Saara Rannanpää; Outi Salminen
Journal:  BMC Neurosci       Date:  2018-11-29       Impact factor: 3.288

6.  Localized co-delivery of CNTF and FK506 using a thermosensitive hydrogel for retina ganglion cells protection after traumatic optic nerve injury.

Authors:  Dongmei Wang; Mengmeng Luo; Baoshan Huang; Wa Gao; Yan Jiang; Qing Li; Kaihui Nan; Sen Lin
Journal:  Drug Deliv       Date:  2020-01-01       Impact factor: 6.419

Review 7.  BDNF as a Promising Therapeutic Agent in Parkinson's Disease.

Authors:  Ewelina Palasz; Adrianna Wysocka; Anna Gasiorowska; Malgorzata Chalimoniuk; Wiktor Niewiadomski; Grazyna Niewiadomska
Journal:  Int J Mol Sci       Date:  2020-02-10       Impact factor: 5.923

8.  Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia.

Authors:  Mitchell J Bartlett; Andrew J Flores; Tony Ye; Saskia I Smidt; Hannah K Dollish; Jennifer A Stancati; Drew C Farrell; Kate L Parent; Kristian P Doyle; David G Besselsen; Michael L Heien; Stephen L Cowen; Kathy Steece-Collier; Scott J Sherman; Torsten Falk
Journal:  Exp Neurol       Date:  2020-07-25       Impact factor: 5.330

9.  AAV-Syn-BDNF-EGFP Virus Construct Exerts Neuroprotective Action on the Hippocampal Neural Network during Hypoxia In Vitro.

Authors:  Еlena V Mitroshina; Tatiana A Mishchenko; Alexandra V Usenko; Ekaterina A Epifanova; Roman S Yarkov; Maria S Gavrish; Alexey A Babaev; Maria V Vedunova
Journal:  Int J Mol Sci       Date:  2018-08-05       Impact factor: 5.923

Review 10.  Regulation of BDNF-TrkB Signaling and Potential Therapeutic Strategies for Parkinson's Disease.

Authors:  Wook Jin
Journal:  J Clin Med       Date:  2020-01-17       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.